Liu S. Radiolabeled cyclic RGD peptides as integrin αⅤβ3-targeted radiotracers: maximizing binding affinity via bivalency[J]. Bioconjug Chem, 2009, 20(12): 2 199-2 213.
[2]
Carmeliet P. Mechanisms of angiogenesis and arteriogenesis[J]. Nat Med, 2000, 6(4): 389-395.
[3]
Yang M, Gao H, Sun X, et al. Multiplexed PET probes for imaging breast cancer early response to VEGF121/rGel treatment[J]. Mol Pharm, 2011, 8(2): 621-628.
[4]
Yang M, Gao HK, Yan YJ, et al. PET imaging of early response to the tyrosine kinase inhibitor ZD4190[J]. Eur J Nucl Med Mol Imaging, 2011, 38(7): 1 237-1 247.
[5]
Gupta MK, Qin RY. Mechanism and its regulation of tumor-induced angiogenesis[J]. World J Gastroenterol, 2003, 9(6): 1 144-1 155.
[6]
李林法，张敏鸣.肿瘤靶向分子影像[M].北京：科学出版社，2006: 82-86.
[7]
Burke PA, DeNardo SJ, Miers LA, et al. Cilengitide targeting of αⅤβ3 integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts[J]. Cancer Res, 2002, 62(15): 4 263-4 272.
[8]
Cai W, Sam Gambhir S, Chen X. Multimodality tumor imaging targeting integrin αⅤβ3[J]. Biotechniques, 2005, 39(6 Suppl): S14-S25.
Lee S, Xie J, Chen X. Peptides and peptide hormones for molecular imaging and disease -diagnosis[J]. Chem Rev, 2010, 110(5): 3 087-3 111.
[11]
Haubner R, Wester HJ, Reuning U, et al. Radiolabeled αⅤβ3 integrin antagonists: a new class of tracers for tumor targeting[J]. J Nucl Med, 1999, 40 (6): 1 061-1 071.
[12]
Haubner R, Wester HJ, Weber WA, et al. Noninvasive imaging of αⅤβ3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography[J]. Cancer Res, 2001, 6(1): 1 781-1 785.
Beer AJ, Haubner R, Goebel M, et al. Biodistribution and pharmacokinetics of the αⅤβ3-selective tracer 18F-galacto-RGD in cancer patients[J]. J Nucl Med, 2005, (8): 1 333-1 341.
[15]
Haubner R, Weber WA, Beer AJ, et al, Noninvasive visualization of the activated αⅤβ3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD[J]. PLoS Medicine, 2005, 2(3): e70.
[16]
Beer AJ, Lorenzen S, Metz S, et al. Comparison of integrin αⅤβ3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG. J Nucl Med, 2008, 49 (1): 22-29.
[17]
Beer AJ, Niemeyer M, Carlsen J, et al. Patterns of αⅤβ3 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PET[J]. J Nucl Med, 2008, 49(2): 255-259.
[18]
Beer AJ, Grosu AL, Carlsen J, et al. [18F]galacto-RGD positron emission tomography for imaging of αⅤβ3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck[J]. Clin Cancer Res, 2007, 13(22 Pt 1): 6 610-6 616.
[19]
Beer AJ, Haubner R, Sarbia M, et al. Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin αⅤβ3 expression in man[J]. Clin Cancer Res, 2006, 2(13): 3 942-3 949.
[20]
Schnell O, Krebs B, Carlsen J, et al. Imaging of integrin αⅤβ3 expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography[J]. Neuro Oncol, 2009, 11(6): 861-870.
[21]
Hauber R, Beer AJ, Wang H, et al. Positron emission tomography tracers for imaging angiogenesis[J]. Eur J Nucl Med Mol Imaging, 2010, 37(Suppl1): S86-S103.
[22]
Indrevoll B, Kindberg GM, Solbakken M, et al. NC-100717: a versatile RGD peptide scaffold for angiogenesis imaging[J]. Bioorg Med Chem Lett, 2006, 16(6): 6 190-6 193.
[23]
Kenny LM, Coombes RC, Oulie I, et al. Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients[J]. J Nucl Med, 2008, 49(6): 879-886.
[24]
Battle MR, Goggi JL, Allen L, et al. Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled αⅤβ3-integrin and αⅤβ5-integrin imaging agent[J]. J Nucl Med, 2011, 52(3): 424-430.
[25]
McParland BJ, Miller MP, Spinks TJ, et al. The biodistribution and radiation dosimetry of the Arg-Gly-Asp peptide 18F-AH111585 in healthy volunteers[J]. J Nucl Med, 2008, 49(10): 1 664-1 667.
[26]
Morrison MS, Ricketts SA, Barnett J, et al. Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy[J]. J Nucl Med, 2009, 50(1): 116-122.
[27]
Liu Zhaofei, Yan Yongjun. 18F, 64Cu, and 68Ga Labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer [J]. Bioconjugate Chem, 2009, 20: 1 016-1 025.
[28]
Liu Z, Liu S, Wang F, et al. Noninvasive imaging of tumor integrin expression using 18F-labeled RGD dimer peptide with PEG4 linkers[J]. Eur J Nucl Med Mol Imaging, 2009, 36(8): 1 296-1 307.
[29]
Wu Zhanhong, Li Zibo. MicroPET of tumor integrin αⅤβ3 expression using 18F-labeled PEGylated tetrameric RGD peptide, 18F-FPRGD4[J]. Nucl Med, 2007, 48(9): 1 536-1 544.
[30]
Ingrid Dijkgraaf, Cheng-Bin Yim. PET imaging of αⅤβ3 integrin expression in tumours with 68Ga-labelled mono- , di- and tetrameric RGD peptides[J]. Eur J Nucl Med Mol Imaging, 2011, 38: 128-137.
[31]
Liu S, Liu Z, Chen K, et al, 18F-labeled galacto and PEGylated RGD dimers for PET imaging of αⅤβ3 integrin expression[J]. Mol Imaging Biol, 2010, 12(5): 530-538.
[32]
Li ZB, Chen K, Chen X, et al. 68Ga-labeled multimeric RGD peptides for microPET imaging of integrin αⅤβ3 expression[J]. Eur J Nucl Med Mol Imaging, 2008, 35(6): 1 100-1 108.
[33]
Chin FT, Shen B, Liu S, et al. First experience with clinical-grade [18F]FPP(RGD)(2): an automated multi-step radiosynthesis for clinical PET studies[J]. Mol Imaging Biol, 2011.
[34]
Sun X, Yan Y, Liu S, et al. 18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy[J]. J Nucl Med, 2011, 52(1): 140-146.
[35]
Liu Zhaofei, Liu Shuanglong. Noninvasive imaging of tumor integrin expression using 18F-labeled RGD dimer peptide with PEG4 linkers[J]. Eur J Nucl Med Mol Imaging, 2009, 36: 1 296-1 307.
[36]
Li ZB, Wu Z, Chen K, et al. Click chemistry for 18F-labeling of RGD peptides and microPET imaging of tumor integrin alphaⅤbeta3 expression[J]. Bioconjugate Chem, 2007, 18(6): 1 987-1 994.
[37]
Hausner SH, Marik J, Gagnon MK, et al, In vivo positron emission tomography (PET) imaging with an αⅤβ6 specific peptide radiolabeled using 18F-“click” chemistry: evaluation and comparison with the corresponding 4-[18F]fluorobenzoyl- and 2-[18F]fluoropropionyl-peptides[J]. J Med Chem, 2008, 51(19): 5 901-5 904.
[38]
Liu S, Liu H, Jiang H, et al. One-step radiosynthesis of 18F-AlF-NOTA-RGD2 for tumor angiogenesis PET imaging[J]. Eur J Nucl Med Mol Imaging, 2011, (9): 1 732-1 741.
Dumont Rebecca A, Friederike Deininger. Novel 64Cu- and 68Ga-labeled RGD conjugates show improved PET imaging of αⅤβ3 integrin expression and facile radiosynthesis[J]. J Nucl Med, 2011, 52(8): 1 276-1 284.
[42]
Naeun Choi, Sung-Min Kim. The use of the fusion protein RGD-HSA-TIMP2 as a tumor targeting imaging probe for SPECT and PET[J]. Biomaterials, 2011, 32: 7 151-7 158.
[43]
Yan Yongjun, Chen Kai. A new 18F-labeled BBN-RGD peptide heterodimer with a symmetric linker for prostate cancer imaging[J]. Amino Acids, 2011, 41: 439-447.
[44]
Liu Zhaofei, Yan Yongjun. Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using 18F-labeled PEGylated RGD-bombesin heterodimer 18F-FB-PEG3-Glu-RGD-BBN[J]. J Med Chem, 2009, 52: 425-432.
